OncoMed Begins Patient Dosing In Phase 2 Clinical Trial Of Tarextumab In Small Cell Lung Cancer
December 01, 2014 at 08:32 AM EST
OncoMed Pharmaceuticals, Inc. (Nasdaq: OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells ...